Literature DB >> 24573422

Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology.

Demetra S Tsapepas1, Jaclyn T McKeen2, Spencer T Martin3, Jennifer K Walker-McDermott1, Alex Yang4, Jamie Hirsch5, Sumit Mohan5, Ruchi Tiwari1.   

Abstract

Risk evaluation and mitigation strategies (REMS) required by the Food and Drug Administration are implemented to manage known or potential risks associated with medications and to ensure ongoing safe use throughout the life of a pharmaceutical agent. Healthcare organizations have begun to adopt information technologies with clinical decision support (CDS) to ensure safe use of medications. Systems have been expanded and customized to also ensure compliance with regulatory standards. End users who are unfamiliar with particular medication use provisions are at risk of unknowingly inappropriately fulfilling specific components. Institution-specific customization of vendor-provided CDS is useful to enhance provider awareness and ensure compliance with standards. Integration of health information technology systems to fulfill REMS requirements is novel and important to ensure consistency as healthcare standards evolve. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Keywords:  Immunosuppressants; Medication Safety; Risk Evaluation Mitigation Strategy; Transplantation

Mesh:

Substances:

Year:  2014        PMID: 24573422      PMCID: PMC4173178          DOI: 10.1136/amiajnl-2013-002446

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  17 in total

1.  An update on risk evaluation and mitigation strategies in transplantation.

Authors:  S Gabardi; P F Halloran; J Friedewald
Journal:  Am J Transplant       Date:  2011-10-25       Impact factor: 8.086

2.  Summary of the US FDA approval of belatacept.

Authors:  P Archdeacon; C Dixon; O Belen; R Albrecht; J Meyer
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

3.  Physician perspective on computerized order-sets with embedded guideline information in a commercial emergency department information system.

Authors:  Phillip V Asaro; Amy L Sheldahl; Douglas M Char
Journal:  AMIA Annu Symp Proc       Date:  2005

4.  Developing and implementing clinical decision support for use in a computerized prescriber-order-entry system.

Authors:  Bruce W Chaffee; Christopher R Zimmerman
Journal:  Am J Health Syst Pharm       Date:  2010-03-01       Impact factor: 2.637

5.  Managing risk in developing transplant immunosuppressive agents: the new regulatory environment.

Authors:  S Gabardi; P F Halloran; J Friedewald
Journal:  Am J Transplant       Date:  2011-08-09       Impact factor: 8.086

6.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

7.  A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.

Authors:  Steven Gabardi; Eric M Tichy
Journal:  Prog Transplant       Date:  2013-03       Impact factor: 1.187

Review 8.  Costs and benefits of health information technology.

Authors:  Paul G Shekelle; Sally C Morton; Emmett B Keeler
Journal:  Evid Rep Technol Assess (Full Rep)       Date:  2006-04

Review 9.  Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review.

Authors:  Simon R Knight; Neil K Russell; Leticia Barcena; Peter J Morris
Journal:  Transplantation       Date:  2009-03-27       Impact factor: 4.939

10.  Phase IV of Drug Development.

Authors:  Viraj Suvarna
Journal:  Perspect Clin Res       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.